No hyperalgesia following opioid withdrawal after the oripavine derivative etorphine compared to remifentanil and sufentanil

European Journal of Anaesthesiology

Volumn 27, Issue 2, 2010, Pages 174-180

  Freye, Enno ^a,b   Levy, Joseph V ^c  

^a Clinics of Vascular Surgery   (Germany)

^b Center of Ambulatory Pain Medicine   (Germany)

^c UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

Etorphine; Nociception; Opioid hyperalgesia; Remifentanil; Sensory evoked potentials; Skin twitch reflex; Sufentanil

Indexed keywords

ETORPHINE; NALOXONE; OPIATE; REMIFENTANIL; SUFENTANIL; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRADYCARDIA; CONTROLLED STUDY; DOG; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG WITHDRAWAL; EVOKED SOMATOSENSORY RESPONSE; HEART RATE; HYPERALGESIA; HYPOTENSION; MEAN ARTERIAL PRESSURE; MUSCLE TWITCH; NOCICEPTION; NONHUMAN; OPIOID INDUCED HYPERALGESIA; POSTOPERATIVE PAIN; WAKEFULNESS; ANIMAL; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; SENSORY NERVE; WITHDRAWAL SYNDROME;

AFFERENT PATHWAYS; ANALGESICS, OPIOID; ANIMALS; BLOOD PRESSURE; BRADYCARDIA; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETORPHINE; EVOKED POTENTIALS, SOMATOSENSORY; HEART RATE; HYPERALGESIA; HYPOTENSION; NALOXONE; NARCOTIC ANTAGONISTS; PIPERIDINES; SUBSTANCE WITHDRAWAL SYNDROME; SUFENTANIL;

EID: 77950343761     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1097/EJA.0b013e32832ff528     Document Type: Article

References (68)

1. Angst MS, Koppert W, Pahl I, et al. Short-term infusion of the μ-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain 2003; 106:49-57.
2. Crawford MW, Hickey C, Zaarour C, et al. Development of acute opioid tolerance during infusion of remifentanil for pediatric scoliosis surgery. Anesth Analg 2006; 102:1662-1667.
3. Siniscalchi A, Piraccini E, Miklosova Z, et al. Opioid-induced hyperalgesia and rapid opioid detoxification after tacrolimus administration. Anesth Analg 2008; 106:645-646.
4. Okon TR, George ML. Fentanyl-induced neurotoxicity and paradoxic pain. J Pain Symptom Manage 2008; 35:327-333.
5. Rivat C, Laulin JP, Corcuf JB, et al. Fentanyl enhancement of carrageenaninduced long-lasting hyperalgesia in rats. Anesthesiology 2002; 96:381-391.
6. Kiss I, Degryse AD, Bardin L, et al. The novel analgesic, F 13640, produces intra- and postoperative analgesia in a rat model of pain. Eur J Pharmacol 2005; 523:29-39.
7. Chakrabarti S, Yang W, Law P, Loh H. The mu-opioid receptor downregulates differently from the delta-opioid receptor: Requirement of a high affinity receptor/G protein complex formation. Mol Pharmacol 1997; 52:105-113.
8. Cvejic S, Trapaidze N, Cyr C, Devi LA. Thr353, located within the COOH-terminal tail of the delta opiate receptor, is involved in receptor down-regulation. J Biol Chem 1996; 271:4073-4076.
9. Mao J, Price DD, Mayer DJ. Thermal hyperalgesia in association with the development of morphine tolerance in rats: Roles of excitatory amino acid receptors and protein kinase C. J Neurosci 1994; 14:2301-2312.
10. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: A current view of their possible interaction. Pain 1995; 62:259-274.
11. Celerier E, Rivat C, Jun Y, et al. Long-lasting hyperalgesia induced by fentanyl in rats: Preventive effect of ketamine. Anesthesiology 2000; 92:465-472.
12. Keith D, Murray S, Zaki P, et al. Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 1996; 271:19021-19024.
13. Arden JR, Segredo V, Wang ZQ, et al. Phosphorylation and agonistspecific intracellular trafficking of an epitope-tagged mu-opioid receptor expressed in HEK 293 cells. J Neurochem 1995; 65:1636-1645.
14. Jordan B, Cvejic S, Trapaidze N, et al. Agonist mediated internalization of the mu, delta and kappa opioid receptor types. New Orleans, Louisiana: Annual Meeting Society of Neuroscience; 1997. p. 691-696.
15. Crain SM, Shen KF. Opioids can evoke direct receptor mediated excitatory effects on sensory neurons. TIPS 1990; 11:77-81.
16. Wang HY, Burns LH. Gßγ that interacts with adenylyl cyclase in opioid tolerance originates from a Gs protein. J Neurobiol 2006; 66:1302-1310.
17. Célèrier E, Laulin JP, Corcuff JB, et al. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: A sensitization progress. J Neurosci 2001; 21:4074-4080.
18. Vinik HR, Kissin I. Rapid development of tolerance to analgesia during remifentanil infusion in humans. Anesth Analg 1998; 86:1307-1311.
19. Crain SM and Shen KF. Etorphine elicits unique inhibitory-agonist and excitatory-antagonist actions at opioid receptors on sensory neurons: New rationale for improved clinical analgesia and treatment of opiate addiction. In: Rapaka RS and Sorer H, editors. Discovery of novel opioids. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health; 1995. pp. 232-268.
20. Wang DX, Liu YS, Qin BY. Experimental treatment of dihydroetorphine and naloxone on morphine-dependent rats and monkeys. Chin J Pharmacol Toxicol 1992; 6:36-40.
21. Richards ML, SadéeW. In vivo opiate receptor binding of oripavines in μ, δ, and κ sites in rat brain as determined by an ex vivo labelling technique. Eur J Pharmacol 1985; 114:343-353.
22. Perry DC, Rosenbaum JS, Kursowski M, Sadee W. 3H-Etorphine receptor binding in vivo: Small fractional occupancy elicits analgesia. J Pharmacol Exp Ther 1982; 21:272-279.
23. Hawkinson JE, Acosta-Burruel M, Espitia SA. Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors. Eur J Pharmacol 2000; 389:107-114.
24. Rosenbaum JS, Holford NHG, Sadee W. Opiate receptor binding-effect relationship: Sufentanil and etorphine produce analgesia at the m-site with low fractional receptor occupancy. Brain Res 1984; 291:317-324.
25. Aubrun F, Valade N, Coriat P, Riou B. Predictive factors of severe postoperative pain in the postanesthesia care unit. Anesth Analg 2008; 106:1535-1541.
26. Guignard B, Bossard AE, Coste C, et al. Acute opioid tolerance: Intraoperative remifentanil increases postoperative pain and morphine requirements. Anesthesiology 2000; 93:409-417.
27. Schmidt S, Bethge C, Forster M, Schafer M. Enhanced postoperative sensitivity to painful pressure stimulation after intraoperative high dose remifentanil in patients without significant surgical site pain. Clin J Pain 2007; 23:605-611.
28. Bentley KW, Hardy DG. Novel analgesics and molecular rearrangements in the morphine-thebaine group. Part III: Alcohols of the 6,14-endoethenotetra- hydrooripavine series and derived analogs of nallylnormorphine and -norcodeine. J AmChem Soc 1967; 89:3281-3292.
29. Gardell LR, King T,Ossipov h, et al. Opiate receptor mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery. Neurosci Lett 2006; 396:44-49.
30. Crain SM, Shen KF. Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice. Brain Res 2007; 1167:31-41.
31. Houde RW, Wikler A. Delineation of the skin-twitch response in dogs and the effects thereon of morphine, thiopental and mephensin. J Pharmacol Exp Ther 1951; 103:236-242.
32. Freye E, Schmidhammer H, Latasch L. 14-Methoxymetopon, a potent opioid, induces no respiratory depression, less sedation, and less bradycardia than sufentanil in the dog. Anesth Analg 2000; 90:1359-1364.
33. Wauquier A. Neurophysiologische Untersuchungen mit dem kurzwirksamen, intravenösen Analgetikum Alfentanil. In: Doenicke A, editor. Alfentanil. Berlin, Heidelberg, New York, Tokyo: Springer; 1982. pp. 78- 89.
34. Buchsbaum MS, Davis GC, Naber D, Pickar D. Pain enhances naloxoneinduced hyperalgesia in humans as assessed by somatosensory-evoked potentials. Psychopharmacology 1983; 79:99-103.
35. Freye E, Levy JV. Constitutive opioid receptor activation: A prerequisite mechanism involved in acute opioid withdrawal. Addict Biol 2005; 10:131-137.
36. Crain SM, Shen KF. GM1 ganglioside-induced modulation of opioid receptor-mediated functions. Ann N Y Acad Sci 1998; 845:106-125.
37. Cruciani RA, Rossi GC, Pasternak GW. Antisense oligonucleotides to Gsa prevents the decline of morphine analgesia over time in mice [abstract]. Soc Neurosci 1999; 25:1478.
38. Freye E, Buhl R, Schenk GK. Somatosensory-evoked potentials (SEP) are effected differently by mu-and kappa-selective opioids in the dog. Funct Neurol 1987; 2:281-292.
39. Buchsbaum MS, Davis GC, Bunney WE. Naloxone alters pain perception and somatosensory evoked potentials in normal subjects. Nature 1977; 270:620-622.
40. Chapmann CR, Chen ACN, Harkins SW. Brain evoked potentials as correlates of laboratory pain: A review and perspective. In: Bonica JJ, Liebeskind JC, Albe-Fessard DG, editors. Advances in pain research and therapy. New York: Raven Press; 1979. pp. 791-803.
41. Freye E, Latasch L, Levy JV. S(+)-Ketamine attenuates increase in electroencephalograph activity and amplitude height of sensory-evoked potentials during rapid opioid detoxification. Anesth Analg 2006; 102:1439-1444.
42. De Pascalis V, Cacace I, Massicolle F. Focused analgesia in waking and hypnosis: Effects on pain, memory, and somatosensory event-related potentials. Pain 2008; 134:197-208.
43. Davis MP, Shaiova LA, Angst MS. When opioids cause pain. J Clin Oncol 2007; 28:4497-4498.
44. Sjörgen P, Thuneborg LP, Christrup L, et al. The development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration ? Six case histories. Acta Anaesthesiol Scand 1998; 42:1070-1075.
45. De Conno F, Caraceni A, Martini C, et al. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain 1991; 47:337-339.
46. Angst MS, Clark JD. Opioid-induced hyperalgesia: A qualitative systematic review. Anesthesiology 2006; 104:570-587.
47. Mercadante S, Arcuri E. Hyperalgesia and opioid switching. Am J Hosp Palliat Care 2006; 22:291-294.
48. Dumont H, Guntz E, Sosnowski M, Talla G. Opioid-induced hyperalgesia. Eur J Anaesthesiol 2007; 24:205-207.
49. Mao J, Price DD, Caruso FS, Mayer D. Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats. Pain 1996; 67:361-368.
50. Cruciani RA, Lussier D, Miller-Saultz D, Arbuck DM. Ultra-low dose oral naltrexone decreases side effects and potentiates the effect of methadone. J Pain Symptom Manage 2003; 25:491-494.
51. Leri F, Burns LH. Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats. Pharmacol Biochem Behav 2005; 82:252-262.
52. Burns LH, Vanderah TW, Wang H-Y. Ultra-low-dose antagonists enhance opioid analgesia and reduce tolerance. In: Dean RL, Bilsky EJ, Negus SS, editors. Opiate Receptors and Antagonists-from Bench to Clinic. New York: Humana Press; 2009. pp. 3-17.
53. Shen K-F, Crain SM. Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance dependence in mice. Brain Res 1997; 757:176-190.
54. Crain SM, Shen K-F. Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia. Brain Res 2001; 888:75-82.
55. Wang H-Y, Friedman E, Olmsteda MC, Burns LH. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in Mu opioid receptor-G protein coupling and Gβγ signaling. Neuroscience 2005; 135:247-261.
56. Powell KJ, Abul-Husn NS, Jahmandas A, et al. Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats. J Pharmacol Exp Ther 2002; 300:588-596.
57. Levine JD, Gordon NC, Taiwo YT, Coderre TJ. Potentiation of pentazocine analgesia by low dose naloxone. J Clin Invest 1988; 82:1574-1577.
58. Gan TJ, Ginsberg B, Glass PSA, et al. Opioid-sparing effect of low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology 1997; 87:1075-1081.
59. Schmidt BL, Gear RW, Levine JD. Response of neuropathic trigeminal pain to the combination of low-dose nalbuphine plus naloxone in humans. Neurosci Lett 2003; 343:144-146.
60. Chindalore VL, Craven RA, Butera PG, et al. Adding ultra-low-dose naltrexone to oxycodone enhances and prolongs analgesia. J Pain 2005; 6:392-399.
61. Blane BF, Boura ALA, Fitzgerald AE, Lister RE. Actions of etorphine hydrochloride (M99): A potent morphine-like agent. Br J Pharmacol Chemother 1967; 30:11-22.
62. Lange DG, Fujimoto JM, Fuhrman-Lane CL, Wang RIH. Unidirectional noncross tolerance to etorphine in morphine-tolerant mice and role of the blood-brain barrier. Toxicol Appl Pharmacol 1980; 54:177-186.
63. Blane GF, Robbie DS. Trial of etorphine hydrochloride (M99 Reckitt) in carcinoma pain, preliminary report. Proc Br Pharmacol Soc 1970; 20:252-253.
64. Tokuyama S, Nakamura F, Nakao K, et al. A potent mu-opioid receptor agonist, dihydroetorphine, fails to produce the conditioned place preference in mice. Jpn J Pharmacol 1996; 71:357-360.
65. Xiao-Yun M, Wei W, Ji-Sheng H, Fei L. Tramadol and dihydroetorphine produce synergistic analgesic effect and postpones acute opiate tolerance in rats. Acta Physiol Sin 2005; 57:696-704.
66. Aceto MD, Harris LS, Bowman ER. Etorphines: μ-opioid receptor-selective antinociception and low physical dependence capacity. Eur J Pharmacol 1997; 338:215-223.
67. Tolkovsky AM. Etorphine binds to multiple opiate receptors of the caudate nucleus with equal affinity but with different kinetics. Mol Pharmacol 1982; 22:648-656.
68. Ohmori S, Hayashi T, Kawase M, et al. Pharmacokinetic and pharmacodynamic evaluations of a potent analgesic, dihydroetorphine, in hairless rat. J Pharmacol Exp Therap 2001; 296:528-536.